^
    2d
    EAY131-Z1K: Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    BRAF mutation • HRAS mutation
    |
    ipatasertib (RG7440)
    2d
    CAVALRY: CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL (clinicaltrials.gov)
    P1/2, N=104, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Truqap (capivasertib) • nelarabine
    2d
    Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer. (PubMed, Signal Transduct Target Ther)
    PK/PD-guided screening on the NOCS prioritized Paxalisib, which, when combined with the exon skipping approach, demonstrated synergistic anticancer efficacy in patient-derived tumor models. These findings establish a clinically relevant framework that integrates multi-organ PK/PD modeling with genotype-driven therapeutic strategies, highlighting the potential of combining targeted gene correction with small-molecule therapy for personalized treatment. This platform offers broad applicability in precision oncology and drug development across diverse genetic contexts.
    PK/PD data • Journal
    |
    NF1 (Neurofibromin 1)
    |
    paxalisib (GDC-0084)
    3d
    Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Sabine Mueller, MD, PhD
    New P2 trial
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCD3 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily D, Member 3)
    |
    gemcitabine • paxalisib (GDC-0084)
    3d
    A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants (clinicaltrials.gov)
    P1, N=20, Completed, AstraZeneca | Recruiting --> Completed
    Trial completion
    |
    Truqap (capivasertib)
    4d
    Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning. (PubMed, Hematology)
    Potential therapeutic agents (e.g. capivasertib, lenalidomide) were predicted, and lenalidomide may represent a feasible initial treatment option for PTCL, with an objective response rate (ORR) of 40.0% and a maximum survival duration exceeding 50 months. NET-RGs play crucial roles in diagnosis, prognosis, and TME regulation, and lenalidomide, a putative TNF-targeting agent, may represent a feasible initial treatment option in PTCL.
    Journal
    |
    AKT2 (V-akt murine thymoma viral oncogene homolog 2) • IRF1 (Interferon Regulatory Factor 1) • MAPK14 (Mitogen-Activated Protein Kinase 14)
    |
    lenalidomide • Truqap (capivasertib)
    7d
    RHBDD1 promotes cervical cancer progression by activating the EGFR/PI3K/AKT signaling pathway. (PubMed, Arch Biochem Biophys)
    RHBDD1 facilitates CC progression by promoting proliferation, EMT, migration, invasion, and tumorigenesis through activation of the EGFR/PI3K/AKT pathway, likely via direct receptor-level interaction. Targeting this regulatory node may offer a promising therapeutic approach for CC.
    Journal
    |
    SNAI1 (Snail Family Transcriptional Repressor 1)
    |
    gefitinib • LY294002
    8d
    MEK1/2 Inhibitor (U0126) and PI3K Inhibitor (LY294002) Suppress Herpes Simplex Virus Type 1 Replication by Targeting MAPK/ERK1/2 and PI3K/AKT Signaling Pathways: Implications for Oral Health and Translational Control of Orolabial HSV-1 Infection. (PubMed, Iran J Pharm Res)
    These findings position MEK1/2 and PI3K as promising therapeutic nodes for managing cutaneous HSV-1 infections. This host-directed dual-pathway inhibition may therefore help reduce recurrent orolabial HSV-1 lesions.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • MAPK1 (Mitogen-activated protein kinase 1)
    |
    LY294002
    10d
    Ginkgetin alleviates UV-induced skin photoaging by reducing oxidative stress and promoting DNA repair via AKT-mediated homologous recombination repair. (PubMed, J Photochem Photobiol B)
    GK may serve as a potential therapeutic candidate for UV-induced photoaging by virtue of its dual capacity to scavenge ROS and enhance AKT-mediated DNA repair.
    Journal • BRCA Biomarker • IO biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • BCL2 (B-cell CLL/lymphoma 2) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • MMP2 (Matrix metallopeptidase 2) • MMP1 (Matrix metallopeptidase 1)
    |
    MK-2206
    10d
    NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation. (PubMed, Adv Sci (Weinh))
    Drug screening identified the HIV protease inhibitor nelfinavir as a specific disruptor of the NIBAN2-FLII complex...Collectively, this study, for the first time, reveals that NIBAN2 maintains GSCs stemness by activating FLII-RREB1 axis and TLR3 signaling, thereby establishing a feed-forward signaling-transcription-metabolism axis. This finding provides a novel strategy and potential targets for precise therapeutic intervention against glioma stemness.
    Journal • IO biomarker
    |
    LDHA (Lactate dehydrogenase A) • CD44 (CD44 Molecule) • SOX2 • TLR3 (Toll Like Receptor 3) • RREB1 (Ras Responsive Element Binding Protein 1)
    |
    Viracept (nelfinavir)
    10d
    NELCER: Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix (clinicaltrials.gov)
    P3, N=348, Completed, Tata Memorial Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • Viracept (nelfinavir) • ondansetron intravenous
    11d
    Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant (clinicaltrials.gov)
    P=N/A, N=48, Completed, AstraZeneca | Recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)